Arbutus Biopharma Corp - 10-Q Filing
Arbutus Biopharma reported Q1 2026 revenue of $179.1 million, driven by a $178.7 million license receivable from Genevant and collaboration income. This compares to $1.8 million in the same period last year. The company recorded net income of $169.7 million due primarily to high royalty and licensing revenue, versus a loss of $24.5 million in Q1 2025.
Tickers: $ABUS